Conclusions
Abnormal coagulation, hyperlactatemia, coagulopathy, septic
COAGULOPATHY
Abnormal coagulation and hyperlactatemia in septic patients with high endotoxin activity appear to be helpful to identify patients who may benefit most from PMX-HA. Our findings will inform enrollment criteria for future interventional trials targeting patients with coagulopathy and hyperlactatemia.